Salinomycin

53003-10-4

C42H70O11

751.00

White or off-white solid

Methanol: 10 mg/mLWater: Insoluble

Source: Streptomyces albus
Identification: Positive
Purity Level: (HPLC, As Is): ≥ 90.0%

-20°C

Spectrum: Salinomycin targets primarily the Gram-positive cell wall to allow ion transport into the cell. Gram-negative organisms are unaffected by Salinomycin because of their additional outer membrane. Salinomycin is also effective against mycobacteria, some filamentous fungi, and Coccidia.

Microbiology Applications: Salinomycin is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative MIC values include:
Clostridium perfringins 0.12 µg/mL – 0.25 µg/mL

Cancer Applications: Salinomycin is a promising anti-cancer agent which selectively targets cancer stem cells. Cancer stems cells (CSCs) are a subpopulation of cells within tumors that drive tumor growth and recurrence. They are resistant to many current cancer treatments. Salinomycin shows selective toxicity for the CSCs that exist as a subpopulation within HMLER breast cancer cells. A Salinomycin treatment of 4T1 and MCF-7-Ras breast cancer cell lines results in a reduction of CSCs. Treatment of 5 mg/kg Salinomycin in mice implanted with SUM159 human breast cancer cells inhibits mammary tumor growth and induces increased epithelial differentiation of tumor cells.The mechanism(s) for the anti-cancer properties of Salinomycin are still unclear, activation of unconventional pathways of cell death, enhanced DNA damage, and inhibition of Wnt signaling pathway, appear to be plausible mechanisms for the multi-dimensional anti-CSC and anti-tumorigenic activities of Salinomycin. Salinomycin was shown to induce apoptosis in human cancer cells and overcomes apoptosis resistance through a pathway independent of activation of p53, caspase, CD95/CD95L system, and the proteasome. Salinomycin in combination with doxorubicin or etoposide led to increased DNA damage and resulted in massive apoptosis in drug resistant cancer cells (Kim et al, 2011). Salinomycin inhibits CD44 expression in breast cancer cells in vitro.